Transaction expected to close at the end of this year for $19 a share.
Alfasigma announced in a company press release that it has entered into a definitive agreement to acquire Intercept Pharmaceuticals for $19 a share in cash. Under terms of the deal, Alfasigma will acquire all issued and outstanding shares of Intercept common stock. Subject to customary conditions, the transaction is expected to close by the end of this year.
The agreement will also include Ocaliva (obeticholic acid), Intercept’s lead medicine, a farnesoid X receptor agonist approved in the United States and several other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
“The acquisition of Intercept marks another important milestone in Alfasigma’s growth path, particularly with regard to the U.S. market in which we have significant development objectives,” said Francesco Balestrieri, CEO, Alfasigma, in the aforementioned release. “Intercept represents a compelling fit with Alfasigma’s core business areas of gastroenterology and hepatology, and we believe that the transaction represents a transformational opportunity for both companies. We are excited to welcome Intercept employees and look forward to working together as we invest in the company to realize the full potential, to the benefit of patients.”
Reference: Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases. GlobeNewswire. September 26, 2023. Accessed September 26, 2023. https://www.globenewswire.com/news-release/2023/09/26/2749452/23024/en/Alfasigma-to-Acquire-Intercept-Pharmaceuticals-for-19-00-per-Share-in-Cash-Expanding-the-Global-Footprint-of-Alfasigma-Via-a-Leader-in-Rare-and-Serious-Liver-Diseases.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.